Verification and application of an automated real-time antimicrobial susceptibility testing system: for accelerated antibiotic susceptibility testing and high-throughput screening of antibiotic synergistic effects

自动化实时抗菌药物敏感性测试系统的验证与应用:用于加速抗生素敏感性测试和高通量筛选抗生素协同作用

阅读:8

Abstract

Bacterial infections remain a serious global health threat, exacerbated by the widespread use of antibiotics leading to bacterial resistance. Faced with the continuous evolution and accelerated spread of drug-resistant bacteria, there is an urgent need to establish an efficient and automated system to accelerate bacterial resistance identification and combination therapy screening in clinical practice. Here, we present an Automated Real-time Antimicrobial Susceptibility Testing (AR-AST) system, which represents an innovation in the AST field by enabling continuous, high-resolution monitoring of microbial growth. This system demonstrated exceptional adaptability, stability, and robustness in monitoring the growth kinetics of six common pathogenic bacteria. Through the establishment of a combined interpretation system of “early bacterial growth kinetics + PPT threshold + slope verification”, it effectively reduces the risk of misclassification. This approach achieved a reduction in the time required for resistance identification of clinical Acinetobacter baumannii 186 and Escherichia coli 15,017 by approximately 75.54% (95% CI: 64.54% − 86.55%) in a hospital setting. Furthermore, when applied to screen pairwise combinations of polymyxin B, polymyxin E, and kanamycin against resistant E. coli15017, a significant synergistic effect was observed for the kanamycin and polymyxin B combination (FIC index = 0.42 < 0.5). The complete inhibition rate in the binary combination was 100% (95% CI: 47.86% − 100%), with a time saving of approximately 68.03% (95% CI: 53.20% − 82.86%). Additionally, the AR-AST System successfully facilitated the quantitative analysis of E. coli15017, exhibiting a broad detection range of six orders of magnitude (10¹ to 10⁶ CFU/mL), high accuracy (|Δ Log₁₀| < ± 0.5), and good stability (P > 0.05), thereby providing effective auxiliary validation for evaluating combination therapy efficacy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13036-026-00630-3.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。